Catheter Precision, Inc. — fact timeline

Catheter Precision, Inc. entered into Securities Purchase Agreement with Volato Group, Inc. valued at $1,000,000 (effective 2026-06-07).

“On June 7, 2026, Catheter Precision, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) between Volato Group, Inc. (NYSE American: SOAR), a Delaware corporation (“Volato”), the Company, and other investors party thereto, pursuant to which the Company agreed to purchase 2,941,176 shares of common stock, par value $0.0001 per share, of Volato (“Shares”) at a per share purchase price of $0.34 per share, for an aggregate purchase price of $1,000,000 (the “Subscription Amount”), in a private placement transaction (the “Private Placement”).”

Catheter Precision, Inc. reported financial results for first quarter of 2026.

“On May 18, 2026, Catheter Precision, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026.”

Catheter Precision, Inc. issued 3,470 shares of preferred stock to the purchasers signatory thereto for aggregate gross proceeds of $3,470,000.

“Issuance of Series C-2 Convertible Preferred Stock On April 21, 2026, Catheter Precision, Inc. (the "Company") consummated the closing (the "Series C-2 Closing") of its previously disclosed sale and issuance of an aggregate of 3,470 shares of the Company's newly designated Series C-2 Convertible Preferred Stock, par value $0.0001 per share and stated value of $1,000 per share (the "Series C-2 Preferred Stock"), for aggregate gross proceeds of $3,470,000.”

Catheter Precision, Inc.: Filed Series C-2 Certificate of Designation designating 3,470 shares as Series C-2 Convertible Preferred Stock and Series D Certificate of Designation designating 11,028 shares as Series D Convertible Preferred Stock (effective 2026-04-17).

“On April 17, 2026, the Company filed each of the Series C-2 Certificate of Designation and the Series D Certificate of Designation with the Secretary of State of the State of Delaware.”

Catheter Precision, Inc. reported the quarter and year ended December 31, 2025 results: revenue $819 thousand, net income $17.2 million.

“create a compelling framework for accelerated growth and a potential re-rating as execution milestones are achieved. 2025 Full Year Financial Highlights ● 2025 Revenue of $819 thousand, a 95% increase over 2024 Revenue of $420 thousand. ● 2025 Gross Margin of 92.3% compared with 90.0% in 2024. ● Net Loss of $17.2 million of which $7.8 million was non-cash”

Catheter Precision, Inc. issued 1,853 shares of Series C-3 Convertible Preferred Stock of preferred stock to accredited investors for aggregate purchase price of $1,853,000.00.

“pursuant to the Financing Purchase Agreement, the Purchasers agreed to purchase (i) 1,853 shares of the Company’s newly-designated Series C-2 Convertible Preferred Stock, with a par value of $0.0001 per share and a stated value of $1,000 per share, for an aggregate purchase price of $1,853,000.00 (the “Series C-2 Preferred Stock”), and (ii) 1,853 shares of the Company’s newly-designated Series C-3 Convertible Preferred Stock, with a par value of $0.0001 per share and a stated value of $1,000 per share, for an aggregate purchase price of $1,853,000.00 (the “Series C-3 Preferred Stock” and, together with the Series C-1 Preferred Stock and Series C-2 Preferred Stock, the “Initial Preferred Stock”)”

Catheter Precision, Inc. issued 1,853 shares of Series C-2 Convertible Preferred Stock of preferred stock to accredited investors for aggregate purchase price of $1,853,000.00.

“pursuant to the Financing Purchase Agreement, the Purchasers agreed to purchase (i) 1,853 shares of the Company’s newly-designated Series C-2 Convertible Preferred Stock, with a par value of $0.0001 per share and a stated value of $1,000 per share, for an aggregate purchase price of $1,853,000.00 (the “Series C-2 Preferred Stock”), and (ii) 1,853 shares of the Company’s newly-designated Series C-3 Convertible Preferred Stock, with a par value of $0.0001 per share and a stated value of $1,000 per share, for an aggregate purchase price of $1,853,000.00 (the “Series C-3 Preferred Stock” and, together with the Series C-1 Preferred Stock and Series C-2 Preferred Stock, the “Initial Preferred Stock”)”

Catheter Precision, Inc. issued 1,853 shares of Series C-1 Convertible Preferred Stock of preferred stock to accredited investors for aggregate purchase price of $1,853,000.

“On March 9, 2026, Catheter Precision, Inc. (the “Company”) entered into a securities purchase agreement (the “Financing Purchase Agreement”) with certain accredited investors (collectively, the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement Financing”) of an aggregate of 1,853 shares of the Company’s Series C-1 Convertible Preferred Stock, with a par value of $0.0001 per share and a stated value of $1,000 per share, initially convertible into up to 1,295,805 shares of common stock, par value $0.0001 per share (“Common Stock”), at an initial conversion price of $1.43 per share (the “Series C-1 Preferred Stock”) for an aggregate purchase price of $1,853,000”

Catheter Precision, Inc.: Amendment to Series C-1 Certificate of Designations to increase authorized shares from 1,783.33 to 3,636.33 (effective 2026-03-06).

“In connection with the entrance into the Financing Purchase Agreement, the holders of the majority of the outstanding shares of Series C-1 Preferred Stock agreed to amend the Series C-1 Certificate of Designations by filing a Certificate of Amendment (“Certificate of Amendment”) to the Series C-1 Certificate of Designations with the Secretary of State of the State of Delaware (the “Secretary of State”) to increase the number of authorized shares of Series C-1 Preferred Stock from 1,783.33 to 3,636.33, in order to authorize a sufficient number of shares of Preferred Stock for the transactions contemplated by the Acquisition Purchase Agreement. On March 6, 2026, the Company filed the Certificate of Amendment with the Secretary of State, thereby amending the Certificate of Designations.”

Catheter Precision, Inc. entered into Financing Purchase Agreement with certain accredited investors valued at an aggregate purchase price of $1,853,000 (effective 2026-03-09).

“On March 9, 2026, Catheter Precision, Inc. (the “Company”) entered into a securities purchase agreement (the “Financing Purchase Agreement”) with certain accredited investors (collectively, the “Purchasers”)”

Catheter Precision, Inc. issued 9,489.488 shares of Series J Preferred Stock of preferred stock to David A. Jenkins and FatBoy Capital, LP for accrued royalty amounts totaling a net present value equal to $9,489,487.81.

“Settlement Agreements dated January 9, 2023 between the Company and the Holders previously disclosed by the Company accrued royalty amounts totaling a net present value equal to $9,489,487.81 as of December 31, 2025 are being exchanged for 9,489.488 shares of Series J Preferred Stock, collectively. Per the Exchange Agreements, the accrued royalty amounts and the”

Catheter Precision, Inc.: Filed Series J Certificate of Designation with Delaware Secretary of State on February 9, 2026, as corrected on February 12, 2026, to establish Series J Convertible Preferred Stock (effective 2026-02-09).

“as further described by the Certificate of Designation of Preferences, Rights and Limitations of Series J Convertible Preferred Stock which was filed with the Delaware Secretary of State on February 9, 2026, as corrected on February 12, 2026 (the "Series J Certificate of Designation")”

Catheter Precision, Inc. entered into Series J Exchange Agreements with David A. Jenkins and FatBoy Capital, LP valued at $9,489,487.81 (effective 2026-02-12).

“On February 12, 2026, Catheter Precision, Inc., a Delaware corporation (the "Company"), entered into Series J Exchange Agreements (the "Exchange Agreements") with David A. Jenkins and FatBoy Capital, LP. (the "Holders") to convert royalty rights and accrued royalty right amounts into 2,491.293 shares and 6,998.195 shares, respectively of the Company's newly created Series J Convertible Preferred Stock”

Catheter Precision, Inc. issued 1,616.33 shares newly-designated Series C-1 Convertible Preferred Stock of preferred stock to certain accredited investors for stated value of $1,000 per share.

“of $1.43 (the “Common Shares”) and (ii) 1,616.33 shares newly-designated Series C-1 Convertible Preferred Stock, with a par value of $0.0001 per share and a stated value of $1,000 per share, initially convertible into up to 1,130,301shares of Common Stock, at an initial conversion price of $1.43 per share (the “Series C-1 Preferred Stock” and, together with”

Catheter Precision, Inc. issued 392,608 shares of common stock to certain accredited investors for $1.43 per share.

“Placement Financing”) of an aggregate of (i) 392,608 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a per share purchase price of $1.43 (the “Common Shares”) and (ii) 1,616.33 shares newly-designated Series C-1 Convertible Preferred Stock, with a par value of $0.0001 per share and a stated value of $1,000 per”

Catheter Precision, Inc.: Filing of Certificate of Designations for Series C-1 Preferred Stock, referenced as a charter amendment under Item 5.03.

“Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. The information contained in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.”

Catheter Precision, Inc. entered into Financing Purchase Agreement with certain accredited investors valued at $2,177,759.00 (effective 2026-02-06).

“On February 6, 2026, Catheter Precision, Inc. (the “Company”) entered into a securities purchase agreement (the “Financing Purchase Agreement”) with certain accredited investors (collectively, the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement Financing”) of an aggregate of (i) 392,608 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a per share purchase price of $1.43 (the “Common Shares”) and (ii) 1,616.33 shares newly-designated Series C-1 Convertible Preferred Stock, with a par value of $0.0001 per share and a stated value of $1,000 per share, initially convertible into up to 1,130,301shares of Common Stock, at an initial conversion price of $1.43 per share (the “Series C-1 Preferred Stock” and, together with the Common Shares, the “Initial Securities”), for an aggregate purchase price of $2,177,759.00 with respect to the Initial Securities”

Catheter Precision, Inc. terminated At-Market-Offering Agreement with Ladenburg Thalmann & Co. Inc. (effective 2025-11-17).

“On November 17, 2025, Catheter Precision, Inc. (the “Company”) delivered notice to terminate its At-Market-Offering Agreement (the “ATM Agreement”), dated as of May 19, 2025, with Ladenburg Thalmann & Co. Inc. (the “Agent”) providing for the Company’s “at‐the‐market” equity offering program (the “ATM Program”), to be effective as of November 24, 2025.”

Catheter Precision, Inc.: Filed certificate of amendment to effect a 1-for-19 reverse stock split of common stock (effective 2025-08-15).

“On August 13, 2025, the Company filed a certificate of amendment to the Company’s restated certificate of incorporation, as amended, with the Secretary of State of the State of Delaware to effect the Reverse Stock Split (the “Charter Amendment”). The Charter Amendment became effective at 12:01 a.m. Eastern Time on August 15, 2025”

David Jenkins was appointed as Chief Commercial Officer at Catheter Precision, Inc..

“Mr. David Jenkins, the Company’s Executive Chairman of the Board and Chief Executive Officer, will fill the role of Chief Commercial Officer until a replacement is engaged.”

Marie-Claude Jacques departed as Chief Commercial Officer at Catheter Precision, Inc..

“On June 2, 2025, Catheter Precision, Inc. (the “Company”) discontinued the employment of Marie-Claude Jacques, the Company’s Chief Commercial Officer.”

Catheter Precision, Inc. incurred loan of $1.5 million with Cardionomic (assignment for the benefit of creditors), LLC at 4% per annum maturing May 5, 2028.

“the issuance by Cardionomix of a promissory note (the "Note") in the amount of $1.5 million, with simple interest accruing at 4% per annum on the principal thereof and no interest or principal payable until the maturity date of the Note, which will be May 5, 2028”

Catheter Precision, Inc. completed an acquisition involving Cardionomic (assignment for the benefit of creditors), LLC for 1,000,000 restricted shares of the Company's common stock and a promissory note in the amount of $1.5 million (closed 2025-05-05).

“or warranties as to merchantability, fitness or use from Seller and no representations from or privity with Assignor, in exchange for the issuance by the Company of 1,000,000 restricted shares of the Company's common stock, $0.0001 par value per share (the “Share Consideration”) and the issuance by Cardionomix of a promissory note (the "Note") in the”

Catheter Precision, Inc. incurred loan of $1.5 million with Cardionomic (assignment for the benefit of creditors), LLC at 4% per annum maturing three years following issuance.

“the issuance by Cardionomix of a promissory note (the "Note") in the amount of $1.5 million, with simple interest accruing at 4% per annum on the principal thereof and no interest or principal payable until the maturity date of the Note, which will be three years following issuance of the Note.”

Margrit Thomassen changed role as Interim Chief Financial Officer at Catheter Precision, Inc..

“Ms. Margrit Thomassen, the Company’s previous Interim Chief Financial Officer, ceased serving in that capacity on January 6, 2025 and will continue in the role of Company Controller.”

Philip Anderson was appointed as Chief Financial Officer at Catheter Precision, Inc..

“On January 4, 2025, the Board of Directors of Catheter Precision, Inc. (the “Company”) appointed Philip Anderson as Chief Financial Officer of the Company, effective January 6, 2025.”

John P. Francis departed as Director at Catheter Precision, Inc..

“On May 15, 2024, John P. Francis informed the Board of Directors of Catheter Precision, Inc. (the “Company”) that he would not stand for reelection to the Board of Directors of the Company at the Company’s 2024 Annual Meeting of Stockholders scheduled for July 3, 2024.”

Catheter Precision, Inc. reported the quarter ended March 31, 2024 results: revenue $82 thousand, net income ($2.7) million.

“were $28 million · Total cash on position at March 31, 2024 was $1.5 million, and $0.5 million at May 6, 2024 · Total revenues for the three months ended March 31, 2024 were $82 thousand · Shareholders’ equity as of March 31, 2024 was $18.5 million · Net loss for the quarter ended March 31, 2024 was ($2.7) million · All revenue as of March 31, 2024 resulted from”

Catheter Precision, Inc. reported the quarter and year ended December 31, 2023 results: revenue $442 thousand, net income ($70.6) million.

“Total revenues for the year ended December 31, 2023 were $442 thousand.”

Catheter Precision, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue $129,000 for the quarter and $442,000 for the year, net income net loss was approximately ($2.5) million for the quarter and ($72.4) million for the year.

“results of the fourth quarter and year ended December 31, 2023, include the following: · Total revenues for the quarter and year ended December 31, 2023, were approximately $129,000 and $442,000, respectively. · Total cash on hand as of December 31, 2023, was approximately $3.6 million. · Total assets as of December 31, 2023, subject to adjustment, was $30.7”

Susanne Meline resigned as Director at Catheter Precision, Inc..

“His appointment fills the vacancy created by the previously reported resignation of Susanne Meline that occurred on December 28, 2023.”

Steve Passey was terminated as Chief Financial Officer at Catheter Precision, Inc..

“Ms. Thomassen replaces Steve Passey, whose employment was terminated on December 28, 2023, effective December 31, 2023.”

Margrit Thomassen was appointed as interim Chief Financial Officer and Secretary at Catheter Precision, Inc..

“In addition, the Board has named Margrit Thomassen, age 53, to serve as interim Chief Financial Officer and Secretary as of the Effective Date.”

David Jenkins was appointed as Chief Executive Officer at Catheter Precision, Inc..

“Also as of the Effective Date, the Board has named David Jenkins Chief Executive Officer of the Company.”

John P. Francis was appointed as Class III director at Catheter Precision, Inc..

“Effective January 2, 2024 (the “Effective Date”), the Board of Directors (the “Board”) of the registrant, Catheter Precision, Inc. (the “Company”), has appointed John P. Francis to serve as a Class III director”

Susanne Meline resigned as Director at Catheter Precision, Inc..

“On December 28, 2023, Susanne Meline tendered her resignation from the Board of Directors of Catheter Precision, Inc. (the “Company”), effective immediately.”

Catheter Precision, Inc. reported three and nine months ended September 30, 2023 results: revenue $314 thousand.

“assets at September 30, 2023, were $32.9 million. · Total cash on hand at September 30, 2023 was $5.6 million. · Total revenues for the nine months ended September 30, 2023 were $314 thousand. David Jenkins, acting CEO, commented: “We are pleased to have the Q3 financial filings completed and have a lot of momentum as we move into the fourth quarter. Our sales and”

Catheter Precision, Inc. reported financial results for the three and six months ended June 30, 2023.

“On December 18, 2023, Catheter Precision, Inc. (formerly known as Ra Medical Systems, Inc.) (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2023.”

Catheter Precision, Inc. received a nyse_american deficiency notice notice regarding late filing (rules 1007).

“August 22, 2023, the Company received a notice from NYSE Regulation stating that the Company is not in compliance with the continued listing standards of the NYSE American under the timely filing criteria set forth in Section 1007 of the NYSE American Company Guide. The non-compliance results from the Company’s failure to timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 by the extended filing due date of August 21, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.”

Catheter Precision, Inc. reported the six months ended June 30, 2023 results: revenue approximately $181,000.

“On August 15, 2023, Ra Medical Systems, Inc. (the “Company”) filed a Form 12b-25 with the Securities and Exchange Commission that estimated that the Company will recognize revenues of approximately $96,000 for the quarter ended June 30, 2023 and approximately $181,000 for the six months ended June 30, 2023.”

Catheter Precision, Inc. reported the quarter ended June 30, 2023 results: revenue approximately $96,000.

“On August 15, 2023, Ra Medical Systems, Inc. (the “Company”) filed a Form 12b-25 with the Securities and Exchange Commission that estimated that the Company will recognize revenues of approximately $96,000 for the quarter ended June 30, 2023 and approximately $181,000 for the six months ended June 30, 2023.”

Catheter Precision, Inc.: Company filed a certificate of amendment to its certificate of incorporation to change its name from Ra Medical Systems, Inc. to Catheter Precision, Inc., effective August 17, 2023 (effective 2023-08-17).

“On August 1, 2023, Ra Medical Systems, Inc., a Delaware corporation (the “Company”), filed a certificate of amendment to its certificate of incorporation with the Secretary of State of Delaware, changing its name to Catheter Precision, Inc. The name change will be effective on August 17, 2023.”

Catheter Precision, Inc. shareholders approved Approval of our 2023 Equity Incentive Plan at the 2023-07-11 meeting.

“Our proposed 2023 Equity Incentive Plan was approved based on the following results of voting: Votes For Votes Against Abstentions 2,382,822 165,641 2,875”

Catheter Precision, Inc. shareholders approved Election of Two Directors at the 2023-07-11 meeting.

“Martin Colombatto was elected at the Annual Meeting as a Class I director to serve a two-year term, and David Jenkins was elected as a Class II director to serve a three-year term, or until their successors are duly elected and qualified, based on the following results of voting: Votes For Votes Against Abstentions Martin Colombatto 2,538,669 12,322 349 David Jenkins 2,539,148 11,841 351”

Catheter Precision, Inc. shareholders rejected Approval of a Proposal to Amend our Certificate of Incorporation to Declassify our Board of Directors at the 2023-07-11 meeting.

“The proposal to amend our certificate of incorporation to declassify our Board of Directors was not approved based on the following results of voting: Votes For Votes Against Abstentions 2,426,765 11,804 112,771”

Catheter Precision, Inc. dismissed Haskell & White LLP as its auditor.

“On the same date, the Committee approved the dismissal of Haskell as the Company’s independent registered accounting firm”

Catheter Precision, Inc. engaged WithumSmith+Brown, PC as its auditor.

“on June 21, 2023, the Committee approved the appointment of Withum as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023”

Catheter Precision, Inc. reported the three months ended March 31, 2023 results: revenue $85 thousand, net income net loss was $66.4 million.

“Passey. · Announced the resignation of its CEO, and appointment of its new Interim CEO, David Jenkins, as of April 28, 2023. · Revenues for the quarter ended March 31, 2023 were $85 thousand, net loss was $66.4 million and cash used by operations was $12.1 million, which includes a $5.0 million cash payment associated with a legacy settlement. Accounting for the”

Catheter Precision, Inc. received a nyse_american deficiency notice notice regarding late filing (rules 1007).

“May 23, 2023, the Company received a notice from NYSE Regulation stating that the Company is not in compliance with the continued listing standards of the NYSE American under the timely filing criteria set forth in Section 1007 of the NYSE American Company Guide. The non-compliance results from the Company’s previously disclosed failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 by the extended filing due date of May 22, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.”

Catheter Precision, Inc. reported the quarter ended March 31, 2023 results: revenue approximately $85,000.

“The Company continues to project revenues for the quarter ended March 31, 2023 of approximately $85,000, and also projects that all or substantially all of its goodwill will be written off as a result of the finalization of the purchase price allocation in connection with the Company’s merger with Catheter Precision, Inc.”